Drug Trial Radar · NCT00623623
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Aug 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,899
Actual
Start
Mar 1, 2008
Primary completion
Sep 1, 2012
Study completion Sep 1, 2012
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 26, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B. The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated. All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.
Conditions
- Myocardial Infarction
Interventions
primary PCIProcedure
Standard primary PCI
enoxaparinDrug
Adjunctive treatment
catheterisationProcedure
Routine or rescue coronary intervention
tenecteplaseDrug
Single, weight-adjusted i.v. bolus of tenecteplase
clopidogrelDrug
Adjunctive treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.Time frame: 30 days
Locations
201 sites in 16 countries. Site status is shown where the registry gives one.
1123.28.43009 Boehringer Ingelheim Investigational Site
Salzburg, Austria
1123.28.43010 Boehringer Ingelheim Investigational Site
Salzburg, Austria
1123.28.43001 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.43002 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.43003 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.43004 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.43005 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.43007 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.43008 Boehringer Ingelheim Investigational Site
Vienna, Austria
1123.28.32060 Boehringer Ingelheim Investigational Site
Bornem, Belgium
1123.28.32010 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1123.28.32070 Boehringer Ingelheim Investigational Site
Herentals, Belgium
1123.28.32040 Boehringer Ingelheim Investigational Site
Liège, Belgium
1123.28.55010 Boehringer Ingelheim Investigational Site
Brasília, Brazil
1123.28.55020 Boehringer Ingelheim Investigational Site
Brasília, Brazil
1123.28.55008 Boehringer Ingelheim Investigational Site
Cabo Frio, Brazil
1123.28.55017 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1123.28.55007 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1123.28.55001 Boehringer Ingelheim Investigational Site
Recife, Brazil
1123.28.55018 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
1123.28.55028 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
1123.28.55016 Boehringer Ingelheim Investigational Site
Sao Lourenço Do Sul, Brazil
1123.28.55004 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1123.28.55014 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1123.28.11006 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
1123.28.11505 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
1123.28.11002 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1123.28.13001 Boehringer Ingelheim Investigational Site
Santiago, Chile
1123.28.13002 Boehringer Ingelheim Investigational Site
Santiago, Chile
1123.28.13003 Boehringer Ingelheim Investigational Site
Santiago, Chile
1123.28.13004 Boehringer Ingelheim Investigational Site
Santiago, Chile
1123.28.13005 Boehringer Ingelheim Investigational Site
Santiago, Chile
1123.28.13006 Boehringer Ingelheim Investigational Site
Santiago, Chile
1123.28.3376A Boehringer Ingelheim Investigational Site
Ambérieu-en-Bugey, France
1123.28.3329A Boehringer Ingelheim Investigational Site
Aubervilliers, France
1123.28.3329B Boehringer Ingelheim Investigational Site
Aubervilliers, France
1123.28.3329C Boehringer Ingelheim Investigational Site
Aubervilliers, France
1123.28.3315A Boehringer Ingelheim Investigational Site
Besançon, France
1123.28.3315B Boehringer Ingelheim Investigational Site
Besançon, France
1123.28.3351A Boehringer Ingelheim Investigational Site
Besançon, France
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.